Navigation Links
BioMarin to Present at the Barclays Global Healthcare Conference
Date:3/8/2011

NOVATO, Calif., March 8, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Barclays Global Healthcare Conference in Miami on Tuesday, March 15, 2011 at 4:15 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Cowen Health Care Conference
2. BioMarin to Present at the Citi Global Healthcare Conference
3. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
4. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
5. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
6. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
7. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
8. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
9. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
10. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
11. BioMarin Announces Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:7/1/2017)... 30, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... conference call will be broadcast live over the Internet on ... news release detailing the quarterly results will be made available ... call. The live audio webcast can be accessed ... It will be archived for replay following the conference call. ...
(Date:6/30/2017)... Medical (AVACEN) announced the publication of new research in the peer-reviewed ... AVACEN Treatment Method to significantly reduce the widespread pain ... ... ... 200 to 400 million people worldwide according to The National Fibromyalgia ...
Breaking Medicine Technology:
(Date:7/20/2017)... Visalia, CA (PRWEB) , ... July 20, 2017 , ... ... has announced the addition of Horine Chiropractic , directed by Dr. Russell Horine, ... as it is completely family run with Dr. Russell Horine serving as the clinic ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today ... received his BS in Biology from LSU, graduating summa cum laude. He attended Emory ... After his residency in St. Louis, Dr. Dunbar moved to New York to complete ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... services since 2014, top travel insurance solution company VisitorsCoverage Inc. has launched TMQuotes, ... all major international travel insurance products online, under their own brand. The online ...
(Date:7/20/2017)... ... ... Dr. Jig Patel is pleased to announce openings for new patients who are ... difficulties that face people who are missing teeth , he offers education about ... and bridges. Not only does an implant improve oral health, it also restores the ...
(Date:7/20/2017)... ... July 19, 2017 , ... ... hiring senior healthcare project manager, Josh Christensen. As a leader in healthcare construction, ... to further its healthcare resume in the Midwest with Josh now on board. ...
Breaking Medicine News(10 mins):